Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” ...

The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing ...

Me’s sale to Regeneron is not yet a done deal. The privacy ombudsman is scheduled to report on the privacy aspects of the ...

Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...

Regeneron Pharmaceuticals was outbid in its effort to buy 23andMe by a nonprofit led by the bankrupt genetics testing company’s co-founder. California-based TTAM Research Institute, led by Anne ...

Beleaguered genetic testing company 23andMe announced Friday that it has reached an agreement to sell itself to TTAM Research ...

Former 23andMe CEO Anne Wojcicki outbids Regeneron with a $305 million offer through her nonprofit TTAM to regain control of the DNA-testing company she co-founded.

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Regeneron Pharmaceuticals had previously agreed to acquire the company for $256 million. TTAM’s higher bid and added consumer protections ultimately led the board’s special committee to select it as ...

Anne Wojcicki's nonprofit is set to purchase all significant assets of the bankrupt genetic testing company, 23andMe, for ...

Anne Wojcicki's nonprofit will acquire substantially all of 23andMe's assets for $305 million, the company announced Friday.

Regeneron’s $256 million acquisition of 23andMe, announced last month, isn’t just a salvage deal — it’s a genomic land grab. A pharmaceutical titan now owns the intimate biological blueprints of 15 ...